WINT Stock Cash Flow Statements

Windtree Therapeutics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Windtree Therapeutics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31

cash flows from operating activities:
net income	10,219,000	-5,154,000	-4,425,000	-6,601,000	-4,111,000	-9,692,000	-4,056,000	-17,333,000	-8,127,000	-13,073,000	-8,213,000	-37,389,000	-8,961,000	-7,454,000	-9,020,000	-9,558,000	-6,534,000	-7,375,000	-7,126,000	-6,437,000	-6,537,000	-9,042,000	-3,927,000	-3,052,000	-4,512,000	2,473,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	21,000	22,000	14,000	23,000	23,000	24,000	21,000	22,000	466,000	52,000	47,000													41,000	41,000	45,000
stock-based compensation	251,000	306,000	305,000	382,000	285,000	791,000	744,000	781,000	770,000	1,622,000	1,629,000	1,544,000	2,443,000	1,281,000	1,148,000	1,566,000	1,689,000	1,513,000	1,939,000	1,739,000	1,530,000	252,000
non-cash lease expense	101,000	100,000	96,000	97,000	116,000	111,000	110,000	133,000	174,000	172,000	169,000	166,000	170,000	-62,000	179,000	179,000	177,000
loss on impairment of goodwill		0	0	2,574,000	484,000	534,000	454,000
gain on debt extinguishment	-14,520,000
unrealized (gain) loss on foreign exchange rate changes	-209,000					231,000	-456,000
changes in assets and liabilities:
prepaid expenses and other current assets	270,000	480,000	311,000	-86,000	218,000	389,000	191,000	257,000	239,000	683,000	503,000	-158,000	337,000	502,000	427,000	234,000	-16,000	299,000	457,000	-73,000	5,000	279,000	-2,000	-268,000	293,000	-174,000
accounts payable	880,000	-135,000	-20,000	211,000	504,000	-161,000	-662,000	348,000	31,000	111,000	294,000	-651,000	-222,000	435,000	-497,000	-178,000	-307,000	345,000	-117,000	-693,000	-2,003,000	-474,000	261,000	-425,000	1,635,000	-722,000
accrued expenses	328,000	-251,000	135,000	114,000	68,000	-940,000	-322,000	-727,000	151,000	-143,000	439,000	-634,000	-69,000	-468,000	628,000	663,000	-238,000	-2,025,000	560,000	-608,000	-1,118,000	-208,000	80,000	118,000	-266,000	-1,168,000
operating lease liabilities	-113,000	-93,000	-106,000	-105,000	-127,000	-120,000	-123,000	-145,000	-183,000	-16,000	-180,000	-176,000	-176,000	43,000	-194,000	-197,000	-190,000	-190,000	-319,000	-251,000	-214,000
other current liabilities	-175,000
net cash from operating activities	-2,947,000	-3,567,000	-3,854,000	-3,497,000	-2,519,000	-3,380,000	-4,099,000	-5,258,000	-6,715,000	-4,932,000	-5,281,000	-7,403,000	-6,048,000	-4,539,000	-8,256,000	-7,038,000	-5,482,000	-5,459,000	-3,824,000	-6,621,000	-8,759,000	-6,191,000	-3,278,000	-3,766,000	-2,546,000	-4,808,000
capex	0	0	0	0	0	0	0	-10,000	-3,000	-173,000	-103,000	0	0	-264,000	-15,000	0	0	-62,000	97,000	-152,000	-74,000	0	0	0	0	0
free cash flows	-2,947,000	-3,567,000	-3,854,000	-3,497,000	-2,519,000	-3,380,000	-4,099,000	-5,268,000	-6,718,000	-5,105,000	-5,384,000	-7,403,000	-6,048,000	-4,803,000	-8,271,000	-7,038,000	-5,482,000	-5,521,000	-3,727,000	-6,773,000	-8,833,000	-6,191,000	-3,278,000	-3,766,000	-2,546,000	-4,808,000
cash flows from financing activities:
proceeds from atm program, net of issuance costs	1,367,000					1,493,000	1,535,000	1,020,000	205,000
principal payments on loans payable	-233,000	-234,000	-233,000	-78,000	-252,000	-377,000	-378,000	-125,000	-294,000	-441,000	-440,000	-2,639,000	-352,000
payments on debt extinguishment	-100,000
proceeds from exercise of common stock warrants, net of expenses		0	0	0	843,000
net cash from financing activities	1,034,000	521,000	-233,000	10,716,000	591,000	1,116,000	1,157,000	895,000	-89,000	2,912,000	-40,000	-1,119,000	27,608,000	48,000	-1,137,000	21,246,000	-199,000					30,417,000	3,279,000	2,542,000	2,500,000	4,871,000
net decrease in cash, cash equivalents, and restricted cash	-1,913,000				-1,928,000
cash, cash equivalents, and restricted cash - beginning of period	4,469,000		0	0	6,326,000		0	0	22,502,000		0	0	17,084,000
cash, cash equivalents, and restricted cash - end of period	2,556,000		-4,102,000	7,219,000	4,398,000		-2,942,000	-4,163,000	15,695,000		-5,424,000	-8,525,000	38,644,000
supplementary disclosure of non-cash activity:
fair value of common stock consideration related to debt extinguishment	280,000
fair value of january 2023 warrant modifications related to the january 2023 warrant exercise inducement		0	0	0	1,238,000
fair value of february 2023 warrant modifications related to the february 2023 warrant exercise inducement		0	0	0	274,000
see notes to condensed consolidated financial statements
loss on impairment of intangible assets										7,250,000	0
loss on sale and disposal of property and equipment		0				0	0
deferred income tax benefit										-1,655,000	0
unrealized gain on foreign exchange rate changes		258,000	-176,000	-106,000	21,000				-236,000				-109,000
cash flows from investing activities:
proceeds from sale of property and equipment						0	0															0	0
purchase of property and equipment		0				0	0	-10,000	-3,000	-173,000	-103,000			-264,000	-15,000			-62,000	97,000	-152,000	-74,000					0
net cash from investing activities		0				0	0	200,000	-3,000	-173,000	-103,000			-264,000	-15,000			-62,000	2,597,000	10,837,000	425,000	-13,736,000	0			0
proceeds from issuance of common stock and warrants, net of issuance costs		0	0							0	0	0	27,390,000	0	0
cash, cash equivalents, and restricted cash - beginning of year
cash, cash equivalents, and restricted cash - end of year
prepayment of insurance through third-party financing		0	0			0	0			0	0
net increase in cash, cash equivalents, and restricted cash			-4,102,000			-2,264,000	-2,942,000	-4,163,000	-6,807,000	-2,193,000	-5,424,000	-8,525,000	21,560,000
non-cash expense related to equity consideration for a service agreement										0	0	0	494,000
proceeds from research and development funding arrangement										200,000	400,000			400,000	1,400,000
operating lease liabilities arising from obtaining right-of-use assets										141,000	0	0	2,000,000
non-cash expense related to warrant modifications														0	0
unrealized loss on foreign exchange rate changes										65,000	31,000
collaboration and device development payable														0	-968,000	-899,000	-108,000	63,000	357,000	-495,000	-692,000
proceeds from atm program, net of expenses										3,153,000	0															0
proceeds from exercise of common stock warrants														0
proceeds from paycheck protection program loan
principal payments on paycheck protection program loan
effect of exchange rate changes on cash and cash equivalents															249,000	520,000	-98,000		-113,000	-136,000	-202,000
depreciation													45,000	42,000	41,000	40,000	42,000	17,000	39,000	89,000	50,000	38,000
amortization of debt discount														0	0	0	3,000	36,000	35,000	37,000	55,000	560,000
changes in:
proceeds from the atm program, net of expenses													570,000
net income on extinguishment of debt
recognition of deferred revenue																		0	0	-158,000	-40,000			-356,000	-204,000
realized gain on investments																			-14,000	-50,000	-11,000
other liabilities																		-112,000	60,000	35,000	24,000
proceeds from sale of marketable securities																			2,500,000	10,989,000	499,000
proceeds from payroll protection program loan														0	0
principal payments on payroll protection program loan
proceeds from private placement issuance of securities, net of expenses																						30,352,000	-1,000			6,071,000
proceeds from loan payable, net of expenses																						1,880,000	1,780,000	0	2,500,000
payments for taxes related to net share settlements of restricted stock units
principle payments on payroll protection program loan															0
principle payments on loans payable															-2,678,000	0	-199,000
payment for taxes related to net share settlements of restricted stock units																			0	0	-151,000
prepayment of insurance through 3rd party financing															0
net increase in cash, cash equivalents and restricted cash
cash, cash equivalents and restricted cash - beginning of period																0	22,732,000		0
cash, cash equivalents and restricted cash - end of period																14,716,000	16,953,000		-1,686,000
net decrease in cash and cash equivalents																	-5,779,000		-1,686,000	4,053,000	-9,134,000
net realized gain on sale of marketable securities
gain on sale of equipment
sale of marketable securities
purchase of marketable securities
cash acquired in cvie acquisition
repayment of loan payable
proceeds from convertible note payable																						0
repayment of convertible note payable
effect of exchange rates on cash and cash equivalents
net increase/(decrease) in cash and cash equivalents																							2,000	-1,216,000	-46,000	63,000
cash, cash equivalents and restricted cash - beginning of year																					11,358,000	0	0	0	2,040,000	0
cash, cash equivalents and restricted cash - end of year																					2,224,000	10,578,000	2,000	-1,216,000	1,994,000	63,000
amortization of operating lease right-of-use assets																			305,000	244,000	192,000
gain on sale of property and equipment																							0
net cash (used in) / provided by financing activities																			-346,000	-27,000	-598,000
prepayment of director and officer insurance through 3rd party financing																			0
principle payments on loan payable																				-27,000	-447,000
amortization of prepaid interest																										94,000
gain on debt restructuring
deferred revenue - current
deferred revenue - non-current
principal payments on debt restructuring
effect of exchange rates on cash
net increase/(decrease) in cash, cash equivalents and restricted cash
supplementary disclosure of cash flows information:
interest paid																										574,000
collaboration payable																							52,000	45,000	49,000	-559,000
deferred revenue
stock-based compensation and 401(k) plan employer match																								140,000	418,000	816,000
fair value adjustment of common stock warrants
loss on sale or disposal of equipment
gain/(loss) on sale or disposal of equipment
proceeds from loan payable
stock–based compensation and 401(k) plan employer match
loss / (gain) on disposal of equipment
inventory
other assets
other liabilities and accrued interest on loan payable
proceeds from issuance of securities, net of expenses
proceeds from exercise of stock options
principal payments of loan payable
principal payments under equipment loan and capital lease obligations
net increase in cash and cash equivalents
cash and cash equivalents as of beginning of year
cash and cash equivalents as of end of year
equipment acquired through capitalized lease
cash flow from operating activities:
stock–based compensation and 401(k) match
loss / (gain) on sale of equipment
cash flow from investing activities:
cash flow from financing activities:
cash and cash equivalents – beginning of year
cash and cash equivalents – end of year
non-cash transactions:

We provide you with 20 years of cash flow statements for Windtree Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Windtree Therapeutics stock. Explore the full financial landscape of Windtree Therapeutics stock with our expertly curated income statements.

The information provided in this report about Windtree Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.